Abstract
Psoriasis patients who are treated with tumour necrosis factor (TNF)-alpha antagonists are at increased risk of reactivation of latent tuberculosis infection (LTBI) and should be adequately screened and monitored during active treatment.
| Original language | English |
|---|---|
| Pages (from-to) | 1572-1576 |
| Number of pages | 5 |
| Journal | Journal of the European Academy of Dermatology and Venereology |
| Volume | 26 |
| DOIs | |
| Publication status | Published - 2012 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- tbc
Fingerprint
Dive into the research topics of 'Clinical applicability of Quantiferon-TB-Gold testing in psoriasis patients during long-term anti-TNF-alpha treatment: a prospective, observational study'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver